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BACKGROUND
==========

Many healthcare organizations and institutions have invested heavily in electronic patient data systems, yet use of health data to optimize personalized prevention, diagnostic, and therapeutic care has been limited. Although many factors contribute to this missed opportunity, the quality, completeness, and accessibility of health system data are major concerns.[@R1]^,^[@R2] Often, health systems purchase data software from multiple vendors for the primary purposes of billing and scheduling, rather than for patient care and evaluation. As a result, multiple nonlinked systems may coexist within a health system but fail to connect essential patient-centered information. Health systems tangled in this data web may require extensive reengineering to effectively access patient data for personalized care, while those early in their development of electronic data systems have an opportunity to build on the successes and avoid the shortcomings of existing systems.

Much of the published evidence of the effectiveness of health information systems to improve health-care has focused on specific components of care. These include medication management (orders, reminders, adverse events, alerts); preventive care reminders and adherence to guidelines; diagnostic aids; chronic disease management; health outcomes; efficiency and cost; and satisfaction.[@R1]^,^[@R3] Studies of these systems in western countries indicate improved care with drug ordering and preventive care reminders but not for health outcomes, resource utilization, or cost, although the lack of effect relates to shortcomings of the studies as well as to the systems themselves.[@R1]^,^[@R3] Characteristics of effective information systems include using in-house systems, developers as users, integrated decision support, and benchmark practices.[@R1] In addition, effective systems address contextual issues related to patients and providers, incentives, interoperability, implementation, improvement, and policies.[@R1]

Despite the lack of evidence to guide the development of effective health information systems, the need to access and fully utilize patient data remains. Connecting disparate data sources to individual patients and across time is an initial step in improving personalized healthcare services and health outcomes, particularly for conditions associated with fragmented care. Breast cancer screening, prevention, and diagnosis provide an example that is important to women. These services often are disjointed and subject to practice variation in the United States.[@R4]^,^[@R5] In addition, essential patient data on mammography and breast procedures often are difficult to extract from radiology and pathology data sources. For example, details of diagnostic breast procedures and pathology diagnoses are generally available only by manually reviewing reports. Diagnosis Related Group (DRG) Current Procedure Terminology or other coding systems indicate only if a procedure resulted in a diagnosis of invasive cancer, ductal carcinoma in situ (DCIS), or nonmalignant lesion. Additional diagnoses are usually embedded within the text fields of dictated pathology reports, limiting their access.

Though breast cancer is considered common in the United States, most women will never have it.[@R6]^,^[@R7] Early detection through screening continues to be an important effort to reduce breast cancer morbidity and mortality, and all women are eligible for breast cancer screening and prevention services over several decades of their lives.[@R4]^,^[@R5] Although barriers to services exist for many women, screening ideally begins with periodic mammography at age 40 or 50 and continues every year or two for 25 years or more.[@R4]^,^[@R5] Approximately 9 to 12 per 1000 women require breast biopsies because of suspicious radiographic lesions after one course of mammography, depending on the woman\'s age.[@R8] Women with physical findings such as breast lumps or skin changes also require breast biopsies. Many will require multiple biopsies during their lifetimes, although accurate cumulative estimates are not available.

Fortunately, for most women, biopsy results do not usually indicate breast cancer. However, simply having had a benign breast biopsy is associated with increased breast cancer risk.[@R9] Several pathological types are considered high-risk lesions, including carcinoma in situ, atypical hyperplasia, and other atypical types. For example, lobular carcinoma in situ (LCIS), atypical ductal hyper-plasia (ADH), and atypical lobular hyperplasia (ALH) increase 10-year breast cancer risk to 17% to 26%.[@R10] The increased detection of high-risk lesions in recent years is related to higher rates of mammography screening and subsequent biopsies of suspicious findings. While screening provides opportunities to identify and reduce cancer risks, it also increases healthcare burdens for women, health systems, and payers.

Although thousands of women are diagnosed with nonmalignant high-risk breast lesions each year, choosing the optimal prevention and diagnostic options is difficult and practice varies. Studies of the effectiveness of clinical management options are lacking. Women at increased risk of breast cancer may require earlier and more frequent mammography, as well as additional imaging modalities, such as breast ultrasound and magnetic resonance imaging (MRI), compared to women at average risk.[@R5]^,^[@R11]In addition, recommendations advise referral of women with significant family histories of breast cancer for genetic counseling and if eligible, to receive genetic testing[@R12] and be considered for risk reduction medications[@R13]^,^[@R14] or surgery. However, women often are unsure about what screening and prevention services would be appropriate for them because services are fragmented, lack uniform standards,[@R15] and are not patient centered.

The purpose of this project is to develop and pilot an integrated and more clinically useful source of health system data related to breast healthcare within a large, community-based health system. The ultimate goal is to use these data to optimize delivery of personalized health care. This study serves as a case example, presenting an approach that would be relevant to other conditions and settings. It focuses on breast cancer screening, prevention, and diagnostic services because of its volume, complexity, fragmentation, and opportunity for improvement and because it connects patient data from existing data sources that currently are difficult to access.

METHODS
=======

Study Design
------------

This study was designed as a quality-improvement project at a large, nonprofit community health system in the United States. A health system clinical team was assembled to guide the project and assure its clinical relevance while working with the health system\'s in-house technology team. The clinical team included health system experts in radiology, pathology, surgery, oncology, primary care, tumor registry, and informatics. Meeting periodically, the team worked collaboratively to create work plans, assess progress, provide clinical updates, and determine data priorities. The project was approved by the Providence Health and Services Institutional Review Board and Privacy Board.

Participants
------------

This project included patients receiving services at Providence Health & Services Oregon (Portland), an integrated health system of eight community hospitals and affiliated outpatient facilities across the state. The health system provides comprehensive care for breast cancer and related conditions, including screening, prevention, diagnosis, treatment, and survivorship care. Patients closely match the demographic and socioeconomic profiles of their communities, including women from inner city, urban, suburban, and rural areas, and many uninsured patients. The volume and diversity of Providence patients and the uniqueness of the health system\'s open-access policies provide an exceptional opportunity for community-based research.

Procedures
----------

Patient-level encounter data from multiple internal sources were identified, mapped to a common data model, linked, and validated to create a breast health-care--specific data mart. Key information sources included demographic and procedural data from administrative data sources and electronic medical records, imaging data from the radiology data system, and pathology data from the laboratory information system ([Figure 1](#F1){ref-type="fig"}). Data from primary sources were integrated and stored in the clinical data warehouse, and a subset of data was extracted to create the breast health--specific data mart. The data mart contains disease-specific data tables, providing an agile data source for customized ad hoc queries. The database structure was designed to interface with current and new data sources, and it undergoes continuous evaluation of the data extract, transform, and load process; data mapping; and validation as health system data sources are changed or upgraded.

![Health system primary data sources.\
Abbreviation: EMR, electronic medical records.](gahmj.2013.054.g001){#F1}

Data from the various primary sources were linked based on matching algorithms using a number of patient identifiers to group data from the same patient. The health system uses a Master Patient Index (MPI) for each unique patient who accesses its extensive clinical network of clinics or hospitals. The data from these encounters are collected in the data warehouse. The MPI and other unique patient identifiers can be used to re-identify patients who leave and reenter the system.

Currently, the data mart involves collection and analysis of existing documents, records, and pathological or diagnostic specimen data that are obtained as part of routine patient care. Additional existing data sources, such as the tumor registry, and potential new sources of quality improvement data, research data, or data provided directly by patients can be linked to the data mart in the future. Patient privacy is maintained by avoiding direct identifiers, such as patient names and social security numbers. Security measures include highly secure and limited access to the database, encryption technology, and use of de-identified data sets for analyses.

The development of data standards for the data mart was based on an adaptation of the common data model ([Figure 2](#F2){ref-type="fig"}). This model can be used to minimize variability and enable common interpretation from multiple data sources. It has been developed and used for drug safety research using large observational data sources, including work by the Observational Medical Outcomes Partnership (OMOP).[@R16] The data standards themselves were modeled after the Breast Cancer Surveillance Consortium (BCSC),[@R17]a National Cancer Institute research collaborative, and the National Accreditation Program for Breast Centers (NAPBC), which has published National Quality Measures for Breast Centers.[@R18] Pathology data were categorized from an electronic pathology database of dictated reports using a standardized lexicon (The Breast Pathology Assessment Tool and Hierarchy for Diagnosis \[BPATHDx\]).[@R19] Data definitions, a data dictionary, and indicators for quality and benchmarking align with these various measures.
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Clinical pathways were developed by the clinical team to outline the patient populations, data elements, decision points, and outcomes for specific conditions. Pathways can be useful in designing a data mart and for subsequent analyses. For a woman with a nonmalignant breast lesion, the clinical pathway generally involves a series of sequential steps including (1) detection of a suspicious finding through routine or diagnostic mammography or physical examination; (2) biopsy and identification of the finding; (3) prevention, diagnostic, and therapeutic decisions that vary according to the pathological lesion, practice patterns, and preferences; and (4) monitoring for subsequent outcomes ([Figure 3](#F3){ref-type="fig"}). For example, most clinicians would recommend surgical excision of ADH and LCIS and 6-month follow-up mammography for any biopsy.[@R15] However, many steps in the pathway are subject to practice variation, and data have not been available to evaluate current practices.
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Measures and Analysis
---------------------

Data describing the distribution of mammography examinations in the health system (by age, year, and indication) and pathological results of breast biopsies (by age, year, and type) served as the main outcome measures for piloting the integrated data mart. These measures were selected because of their clinical importance, the existence of standardized data definitions, and their requirements for data linkages from various data sources. Analysis included descriptive statistics including proportions.

RESULTS
=======

Using these approaches, initial analysis of the data mart indicated that during a 4-year period (2008 to 2011), 200768 screening and 50200 diagnostic mammograms were obtained in the health system ([Table 1](#T1){ref-type="table"}). Mammography rates varied by age and other characteristics over time, such as insurance status.[@R20]

###### 

Mammography Examinations in the Health System 2008--2011, n (%)

  Screening                                                               
  ----------- -------------- -------------- -------------- -------------- --------------
  Age, y      2008           2009           2010           2011           Total
  \<40        1226 (2.4)     995 (2.0)      686 (1.4)      661 (1.3)      3568 (1.8)
  40--49      11934 (23.7)   11179 (22.3)   10173 (20.9)   10965 (21.2)   44251 (22.0)
  50--59      15316 (30.5)   15082 (30.1)   14979 (30.7)   15665 (30.3)   61042 (30.4)
  60--69      11529 (22.9)   12292 (24.6)   12800 (26.3)   14081 (27.2)   50702 (25.3)
  70--79      6709 (13.3)    6864 (13.7)    6769 (13.9)    7118 (13.8)    27460 (13.7)
  ≥80         3584 (7.1)     3651 (7.3)     3306 (6.8)     3204 (6.2)     13745 (6.8)
  Total       50298          50063          48713          51694          200768

  Diagnostic                                                           
  ------------ ------------- ------------- ------------- ------------- --------------
  Age, y       2008          2009          2010          2011          Total
  \<40         1303 (11.2)   1459 (11.2)   1209 (9.7)    1229 (9.4)    5200 (10.4)
  40--49       3334 (28.6)   3640 (28.1)   3491 (28.1)   3610 (27.5)   14075 (28.0)
  50--59       3197 (27.4)   3481 (26.8)   3455 (27.8)   3626 (27.6)   13759 (27.4)
  60--69       2151 (18.4)   2458 (18.9)   2475 (19.9)   2811 (21.4)   9895 (19.7)
  70--79       1094 (9.4)    1239 (9.5)    1187 (9.5)    125 (9.5)     4772 (9.5)
  ≥80          592 (5.1)     697 (5.4)     622 (5.0)     588 (4.5)     2499 (5.0)
  Total        11671         12974         12439         13116         50200

During this period, breast biopsies for 7332 women were evaluated by health system pathologists. Using the diagnostic hierarchy to query the electronic pathology database, the data mart categorized patients into discrete diagnostic groups based on the most clinically significant diagnosis from each specimen, consistent with clinical practice. Results indicated that 23.3% (1709) of patients had invasive breast cancer, 6.7% (491) had DCIS, and 70.0% (5132) had nonmalignant diagnoses that would not have been further differentiated by administrative DRG codes alone ([Table 2](#T2){ref-type="table"}). These included 336 cases of ADH, 89 cases of ALH, 82 cases of LCIS, and 106 cases of other types of atypia (flat epithelial atypia, papillary atypia, apocrine atypia).

###### 

Pathology Results for 7332 Women With Breast Biopsies, n (%)

  Age, y   Invasive cancer   DCIS        LCIS       Atypical hyperplasia[^a^](#TFN2-1){ref-type="table-fn"}   Other atypical types[^b^](#TFN2-2){ref-type="table-fn"}   Intraductal papilloma   Radial Scar   Sclerosing adenosis   Fibro-adenoma   Hyperplasia without atypia[^c^](#TFN2-3){ref-type="table-fn"}   Benign non-proliferative
  -------- ----------------- ----------- ---------- --------------------------------------------------------- --------------------------------------------------------- ----------------------- ------------- --------------------- --------------- --------------------------------------------------------------- --------------------------
  \<40     55                11          2          22                                                        4                                                         48                      7             9                     450             30                                                              377
  40--49   229               94          19         125                                                       27                                                        70                      23            26                    386             98                                                              726
  50--59   418               147         40         134                                                       38                                                        64                      15            27                    201             78                                                              698
  60--69   476               128         11         93                                                        20                                                        56                      4             12                    159             50                                                              466
  70--79   297               69          8          34                                                        11                                                        25                      3             6                     67              21                                                              212
  ≥80      234               42          2          17                                                        6                                                         7                       3             0                     19              8                                                               68
  Total    1709 (23.3)       491 (6.7)   82 (1.1)   425 (6.0)                                                 106 (1.4)                                                 270 (3.7)               55 (0.8)      80 (1.1)              1282 (17.5)     285 (3.9)                                                       2547 (34.7)

Atypical ductal hyperplasia, atypical lobular hyperplasia.

Flat epithelial atypia, papillary atypia, apocrine atypia.

Columnar hyperplasia, usual ductal hyperplasia.

Abbreviations: DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ.

CONCLUSIONS
===========

The creation of a patient-centered data system by connecting and integrating disparate data sources within a large health system allows customized analyses of data. For breast care services, patient-specific data were linked across patient records and administrative, radiology, and pathology data sources. This type of data integration improves the health system\'s capacity to provide individual-level data to support clinical decisions and actualize personalized healthcare.

Next steps require connecting the women\'s biopsy results with data about their prevention, diagnostic, and therapeutic decisions in the clinical pathways and then linking them to long-term outcomes. In addition, associations between patient characteristics and outcomes can be determined in order to identify potential predictors for specific outcomes. These characteristics include age, social and demographic variables, family history of breast cancer, other known risk factors for breast cancer, results of previous imaging studies and biopsies, and clinical breast findings (eg, symptoms, palpable mass and size, etc), among others.

The data mart also requires further evaluation of its validity and efficiency. While validity is generally defined as a measure of the degree of erroneous and missing data, there are no established standards to evaluate the efficiency of clinical data sources. Efficiency can be determined by its accessibility (ie, how easy it is to run queries and pull specific data elements from data stores), format translation (ie, how much translation is required to standardize the data elements in the common data model), completeness (ie, how well the data variable populates patient records), and correctness (ie, how well the data agree with the most reliable source or gold standard). These domains are important in considering the clinical utility of the clinical data sources and are not addressed by validation alone.

Personalized healthcare is enhanced by improving patient access to data sources both within and outside the healthcare setting. Through interactive systems, patients could have multidirectional interactions with healthcare providers and systems to help make appropriate healthcare decisions that improve their health. To date, this project has not provided direct access to patients, but that work is planned.

Personalized healthcare also requires shared informed decision making between patients and clinicians. While this concept has been widely accepted, the development of practical tools, such as decision aids, to support shared decision making has only recently emerged. A 2011 Cochrane review on decision aids reported improved patient knowledge (mean difference 13.77 out of 100; 95% confidence interval \[CI\], 11.40 to 16.15; 26 trials) and risk perception (relative risk \[RR\] 1.75; 95% CI, 1.46 to 2.08; 14 trials) when probabilities were presented to patients compared to usual care.[@R21]Also, decision aids that included values clarification improved the proportion of patients who made decisions consistent with their own priorities or preferences.[@R21]

Decision aids provide women with customized prognostic risk information while engaging them in considering their personal values surrounding the benefits and harms associated with various healthcare options. As a woman begins the decision aid, she uses menus to select key variables to personalize the risk information she receives. Risk information is then presented using various well-accepted approaches including graphics (eg, pictographs) and numerical and text explanations. Each appropriate healthcare option is presented based on evidence-based standards of care, and women are able to set priorities for their decisions. Shared decision-making projects have been prioritized by the clinical team and are in development. These include patient decision aids for screening mammography,[@R22]clinical management after breast biopsy, and breast cancer risk assessment to guide referrals to genetic counseling.

Although this project was conducted in a health system in the United States and focused on a specific clinical condition, its methods can be applied broadly. A clinical team identifying data priorities, defining data elements using a common data model, and creating clinical pathways can be assembled from existing medical staff. A technical team, either in-house or consulting, is required to identify existing data sources or develop them if they are lacking and provide linkages. Each project can be customized to the needs and resources of the health system or institution and modified over time.

The success of this project is based on an incremental approach to extracting relevant data from disparate noninteroperable data systems. The creation of a data warehousing model and a customized data mart is an effective solution. However, true multidirectional information exchange between data sources and the breast health data mart at the point of care, within patient\'s personal health records, and outside the health system will ultimately provide the most personalized connected data system.
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